Halberd Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HALB research report →
Companyhalberdcorporation.com
Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.
- CEO
- William A. Hartman
- IPO
- 2012
- Employees
- 3
- HQ
- Jackson Center, PA, US
Price Chart
Valuation
- Market Cap
- $567.46K
- P/E
- -17.49
- P/S
- 0.00
- P/B
- -0.89
- EV/EBITDA
- -18.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 5.01%
- ROIC
- 5.56%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-20,071 · 74.81%
- EPS
- $0.00 · 100.00%
- Op Income
- $-18,665
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.04
- Avg Volume
- 887.19K
Get TickerSpark's AI analysis on HALB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HALB Coverage
We haven't published any research on HALB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HALB Report →